GlassScriptPhysician profile
Thomas N Bell
NPI 1801248810
$28,972.13
in general payments reported to CMS, 2019-2025
22 companies · $773 in 2025
The $773 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.16 · 2021: $337 · 2022: $18K · 2023: $8,670 · 2024: $1,046 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,136 · Food and Beverage: $3,019 · Education: $333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,136.00 |
| Food and Beverage | $3,019.47 |
| Education | $332.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $24,877.52 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,043.86 | 2021-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $575.42 | 2021-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $361.54 | 2022-2025 | Rayaldee |
| Amgen INC. | $277.73 | 2021-2025 | Tavneos, Krystexxa, Aranesp |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.72 | 2023-2025 | Jardiance |
| Travere Therapeutics, INC. | $181.48 | 2022-2025 | Thiola |
| Novartis Pharmaceuticals Corporation | $176.79 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $173.52 | 2021-2025 | Lupkynis |
| Vifor Pharma, INC. | $158.52 | 2021-2023 | Korsuva, Veltassa |
| Mallinckrodt Hospital Products INC. | $156.67 | 2021-2025 | Acthar |
| Fresenius USA Marketing, INC. | $149.37 | 2022-2025 | Velphoro, Velphoro |
| Ani Pharmaceuticals, INC. | $130.36 | 2022-2025 | Purified Cortrophin Gel |
| Daiichi Sankyo INC. | $127.71 | 2021-2025 | Injectafer |
| Glaxosmithkline, LLC. | $122.16 | 2022-2023 | Benlysta |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $70.89 | 2024-2025 | Ibsrela |
| Akebia Therapeutics INC | $64.97 | 2022 | |
| Calliditas Therapeutics US INC. | $57.76 | 2022-2025 | Tarpeyo |
| Exact Sciences Corporation | $22.42 | 2023 | Cologuard Collection Kit |
| Shire North American Group INC | $21.44 | 2019 | |
| Horizon Therapeutics Plc | $18.56 | 2023 | Krystexxa |
| Pfizer INC. | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.